ESGREV
banner
esgrev-escmid.bsky.social
ESGREV
@esgrev-escmid.bsky.social
ESCMID Study Group for Respiratory Viruses
Pinned
This is the @bsky.app 🦋 account for ESGREV, the Respiratory Virus Study Group of ESCMID, the European Society for Clinical Microbiology and Infectious Diseases. Follow us for #research and #science news!
@escmid.bsky.social
Reposted by ESGREV
🦠 Measles is back. Cases have exploded in 2025 in France, UK, US & Europe due to falling vaccine coverage.

The MMR vaccine is ~100% effective with 2 doses. It's saved 94M lives since 1974.

Measles isn't just for kids – 34% of US cases were adults over 20.

www.pasteur.fr/en/research-...

#Measles
Three questions about measles: why is it on the rise, is the vaccine effective, and can you catch it at any age?
A few years ago, measles seemed to be on the verge of being eradicated in many countries. The recent rise in cases raises several questions. Why is measles making a comeback? Is the measles, mumps and...
www.pasteur.fr
November 24, 2025 at 1:49 PM
Reposted by ESGREV
🌍 World AMR Awareness Week (#WAAW2025)

🎥 Dr Teske Schoffelen introduces the Abx Guide—a free, open-access database that compiles evidence on pathogen-directed antibiotic treatment.

▶️ Watch: youtu.be/XpN_fRG7pCk
@heiman-wertheim.bsky.social @souhakanj.bsky.social
WAAW 2025 | ISAC Abx Guide
YouTube video by ISAC / APUA
youtu.be
November 24, 2025 at 11:54 AM
Reposted by ESGREV
DON'T MISS IT!

From Resistance to Resilience: healthcare workers leading the change.

Join public health professionals, academia, patients' and NGO's representatives and let's talk about the ways to #KeepAntibioticsWorking!

#EAAD2025 online event starts at 1PM CET!
Register: bit.ly/EAAD2025Regi...
November 17, 2025 at 11:10 AM
Reposted by ESGREV
#Respiratory syncytial virus can cause severe illness especially in infants

Data from Belgium, Portugal & Spain show that #immunisation of #children after birth with long-acting monoclonal antibodies 📉 the risk of #hospitalisation due to #RSV infection by ~80%

#IDSky #EpiSky #PedSky #MedSky 🛟🧪
Study in Europe: monoclonal antibodies effectively prevent respiratory syncytial virus in infants
Respiratory syncytial virus can cause severe illness especially in young infants. A new study published in Eurosurveillance shows that immunisation of children after birth reduced the risk of hospital...
www.eurekalert.org
November 14, 2025 at 3:40 PM
Reposted by ESGREV
You can also find more information about #RSV on the European Vaccination Information Portal - #EVIP in YOUR language!

Check it out here: vaccination-info.europa.eu/en/rsv

#UnitedInProtection #VaccinesSaveLives #VaccinesWork #ChildHealth #PublicHealth
RSV
Key facts on RSV symptoms, complications, risk factors, how it spreads, prevention, vaccination and treatment.
vaccination-info.europa.eu
November 13, 2025 at 2:53 PM
Reposted by ESGREV
This winter, raising awareness among healthcare workers & following national recommendations will remain essential to reducing the burden of RSV on infants.

Press release: bit.ly/4qSWLex
Rapid scientific advice: bit.ly/4hTTNSG
Living systematic review: bit.ly/4hVQLxz

#IDsky #EpiSky
Protecting infants against respiratory syncytial virus this winter — ECDC issues advice
ECDC has issued a rapid scientific advice on effective ways to mitigate the impact of RSV disease in infants through immunisation interventions.
bit.ly
November 13, 2025 at 2:53 PM
🛎️
Gut microbiota predicts the risk of future COVID-19 hospitalization and mortality: insights from the population-based HELIUS Study

✅ Just Accepted
🔗 https://bit.ly/47Ag2IA
November 9, 2025 at 8:13 PM
Reposted by ESGREV
🎓 Jetzt anmelden!
Vom 01.–05.12.2025 bietet die Akademie des ZKS Köln wieder den Kurs für Studienkoordination an – als virtuelle Präsenzschulung.
Für Study Nurses & Interessierte, die ins Studienmanagement einsteigen wollen.
👉 zks.uni-koeln.de/akademie/kurs-fuer-studienkoordination
November 6, 2025 at 9:21 AM
Reposted by ESGREV
📜 At #ESWI2025 Maria Zambon traces the history of how we understand pandemics — from religious interpretations to the rise of rational, evidence-based therapeutics
A fascinating look at how science reshaped our view of disease and response🧠
#PublicHealth #Pandemic #History
October 23, 2025 at 6:39 AM
Reposted by ESGREV
Immunization against respiratory syncytial virus delivered to infants following birth is safe and provides high antibody levels, regardless of the mother’s RSV vaccination status, according to new research presented at #IDWeek2025. bit.ly/3J9fIbS
RSV Immunization in Infants Is Safe and Provides High Antibody Levels Regardless of Mother’s Vaccination Status
bit.ly
October 20, 2025 at 5:45 PM
Reposted by ESGREV
✈️ Next stop: #ESWI2025 in Valencia!
We’re excited to join global experts in infectious disease control, antimicrobial stewardship, and vaccine innovation.
Looking forward to sharing insights, forging collaborations, and advancing prevention together.
#VIVI #InfectionPrevention
October 19, 2025 at 2:35 PM
Reposted by ESGREV
➡️ Pediatric myocarditis is more often viral and acute, adults more chronic and immune-mediated
➡️ Diagnosis and treatment draw from adult data, leaving major gaps in paediatric evidence

CCR Journal Watch - tracking the critical care literature daily
criticalcarereviews.com/latest-evide...
October 13, 2025 at 7:05 PM
Reposted by ESGREV
There are a few days left to apply for an ESCMID observership!
ESCMID is awarding 50 young scientists up to 2K EUR to travel to one of the over 100 collaborative centres for knowledge exchange in the fields of CM & ID! Read more and apply before the deadline on Tuesday, 14 October: ow.ly/95BK50X2GRP
October 9, 2025 at 3:01 PM
Reposted by ESGREV
📣🧊 The Trainee Association of ESCMID (TAE) is holding elections for 3 new members in the steering committee. Young Scientist Members (YSM) and LMIC members fulfilling the YSM criteria are eligible to apply. Nominations close 31 October. ow.ly/fHsy50X96Nb
October 13, 2025 at 10:14 AM
Reposted by ESGREV
More than pills and shots — your gut microbiome might be a hidden key to vaccine success. 🌿
Recent research shows gut bacteria affect how well our bodies respond to #vaccines.
Diet, probiotics, and microbiome health = new frontiers in prevention.
#Microbiome #VIVI
September 24, 2025 at 5:37 AM
Reposted by ESGREV
Fantastic session on vaccine licensing covering aspects from fighting ongoing outbreaks, limited clinical data, and the current latest developments in the pipeline. Featuring Marco Cavaleri, Sarah Gilbert, Teresa Lambe and Annelies Wilder-Smith.
@ema.europa.eu #VaccinesConference #Vaccines #IDSky
September 11, 2025 at 11:10 AM
Reposted by ESGREV
🌍 At @ESCMID #VaccinesConference in Lisbon, #Pandemic #Preparedness is in focus (Day 3 & Day 5).
From surveillance to vaccines, global cooperation is key to staying ahead of future threats.
Prevention today means resilience tomorrow.
#UnitedInProtection

👉 bit.ly/ViVI-Prep2025
September 12, 2025 at 1:02 PM
Reposted by ESGREV
This week's rapid communications describe

➡️A strain of Neisseria gonorrhoeae producing false negative results on Xpert CT/NG assay in England

🔎An atypical sixfold rise in #influenza A(H1N1)pdm09 cases in Denmark during summer

Full issue here 👉 bit.ly/eus2036

#EpiSky #IDSky #MedSky #STISky 🛟🦠🧫⚕️
September 11, 2025 at 8:41 PM
Reposted by ESGREV
#JeudiRétro | C’était la polio. Nous nous sommes fait vacciner. Éprouvés. Salvateurs. Les vaccins | www.immunize.ca/sites/defau... #polio #LesVaccinsÇaMarche #LesVaccinsSauventDesVies #FaitesVousVacciner
www.immunize.ca
September 11, 2025 at 10:01 PM
Reposted by ESGREV
Welcome back students! Joining us from 29 different countries hailing from 6 continents across the various degree programs are: 72 PhD students, 15 SM1 students, 13 SM1 summer-only students, 62 SM2 students, and 76 MPH Epi students in the Department of Epidemiology @hsph.harvard.edu.
September 2, 2025 at 7:24 PM
Reposted by ESGREV
Response to Letter to the Editor, Re: The Effect of Nirmatrelvir-Ritonavir on Short- and Long-term Adverse Outcomes From COVID-19 Among Patients With Kidney Disease: A Propensity Score-Matched Study

✅ Just Accepted
#IDSky
Response to Letter to the Editor, Re: The Effect of Nirmatrelvir-Ritonavir on Short- and Long-term Adverse Outcomes From COVID-19 Among Patients With Kidney Disease: A Propensity Score-Matched Study
bit.ly
August 27, 2025 at 7:56 PM
Reposted by ESGREV
Ebola Virus Disease: Uniquely Challenging Among the Viral Hemorrhagic Fevers

CCR Journal Watch - tracking the critical care literature daily
https://criticalcarereviews.com/latest-evidence/journal-watch
August 27, 2025 at 8:38 PM
Reposted by ESGREV
Skin lesions and personal protective equipment (PPE) in healthcare workers from Lima, Peru during the COVID-19 pandemic: a cross-sectional study

✅ Just Accepted
#IDSky
Skin lesions and personal protective equipment (PPE) in healthcare workers from Lima, Peru during the COVID-19 pandemic: a cross-sectional study
During the COVID-19 pandemic, healthcare workers (HCWs) relied on personal protective equipment (PPE) to mitigate COVID-19 infections.
bit.ly
August 26, 2025 at 8:03 PM
Reposted by ESGREV
🧪 Just 1 week left to apply!

ISAC Project Grants 2025 offer up to £15,000 for research in #AMR & #infectiousdiseases
🌍 Projects must involve 2 countries (1 LMIC)
📅 Deadline: 1 Sept
📧 secretariat@ISAC.world
🔗 isac.world
#GlobalHealth #ISACGrants
@heiman-wertheim.bsky.social @souhakanj.bsky.social
August 25, 2025 at 9:37 AM